<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on February 03, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00002102</url>
  </required_header>
  <id_info>
    <org_study_id>132B</org_study_id>
    <secondary_id>TMTX C010</secondary_id>
    <nct_id>NCT00002102</nct_id>
  </id_info>
  <brief_title>A Compassionate Treatment Protocol for the Use of Trimetrexate Glucuronate With Leucovorin Protection for Patients With Pneumocystis Carinii Pneumonia.</brief_title>
  <official_title>A Compassionate Treatment Protocol for the Use of Trimetrexate Glucuronate With Leucovorin Protection for Patients With Pneumocystis Carinii Pneumonia.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>U.S. Bioscience</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>NIH AIDS Clinical Trials Information Service</source>
  <brief_summary>
    <textblock>
      To provide trimetrexate glucuronate to immunosuppressed patients with Pneumocystis carinii&#xD;
      pneumonia (PCP) for whom this investigational compound could provide significant medical&#xD;
      benefit.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Patients receive intravenous infusions of trimetrexate glucuronate and leucovorin for 21&#xD;
      days. Leucovorin is continued for 3 additional days after discontinuation of trimetrexate&#xD;
      glucuronate.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <condition>Pneumonia, Pneumocystis Carinii</condition>
  <condition>HIV Infections</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Trimetrexate glucuronate</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Leucovorin calcium</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria&#xD;
&#xD;
        Concurrent Medication:&#xD;
&#xD;
        Allowed:&#xD;
&#xD;
          -  Antiretroviral therapy (at the discretion of the treating physician and/or medical&#xD;
             monitor).&#xD;
&#xD;
        Patients must have:&#xD;
&#xD;
          -  Presumptive or definitive diagnosis of Pneumocystis carinii pneumonia (PCP).&#xD;
&#xD;
          -  HIV positivity or be otherwise immunosuppressed.&#xD;
&#xD;
          -  Demonstrated intolerance and/or resistance to trimethoprim/sulfamethoxazole during the&#xD;
             course of therapy for the current episode and not candidates for parenteral&#xD;
             pentamidine, OR a documented history of such intolerance during a prior episode.&#xD;
&#xD;
          -  Consent of parent or guardian if less than 18 years of age.&#xD;
&#xD;
        NOTE:&#xD;
&#xD;
          -  In general, patients who meet the eligibility criteria for other U.S.&#xD;
             Bioscience-sponsored clinical trials for trimetrexate would not be eligible for this&#xD;
             Compassionate Use protocol.&#xD;
&#xD;
        Exclusion Criteria&#xD;
&#xD;
        Patients with the following prior conditions are excluded:&#xD;
&#xD;
        History of Type I hypersensitivity (i.e., urticaria, angioedema, or anaphylaxis),&#xD;
        exfoliative dermatitis, or other life-threatening reactions to trimetrexate.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>1 Day</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>United States Bioscience Inc</name>
      <address>
        <city>West Conshohocken</city>
        <state>Pennsylvania</state>
        <zip>19428</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Feinberg J, McDermott C, Nutter J. Trimetrexate (TMTX) salvage therapy for PCP in AIDS patients with limited therapeutic options. Int Conf AIDS. 1992 Jul 19-24;8(2):B136 (abstract no PoB 3297)</citation>
  </reference>
  <verification_date>January 1994</verification_date>
  <study_first_submitted>November 2, 1999</study_first_submitted>
  <study_first_submitted_qc>August 30, 2001</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 31, 2001</study_first_posted>
  <last_update_submitted>June 23, 2005</last_update_submitted>
  <last_update_submitted_qc>June 23, 2005</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 24, 2005</last_update_posted>
  <keyword>Trimetrexate</keyword>
  <keyword>Pneumonia, Pneumocystis carinii</keyword>
  <keyword>Leucovorin</keyword>
  <keyword>Drug Therapy, Combination</keyword>
  <keyword>Acquired Immunodeficiency Syndrome</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pneumonia</mesh_term>
    <mesh_term>Pneumonia, Pneumocystis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leucovorin</mesh_term>
    <mesh_term>Trimetrexate</mesh_term>
    <mesh_term>Calcium</mesh_term>
    <mesh_term>Levoleucovorin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

